ClinicalTrials.gg
RecruitingNCT07530718BCOMSUpdated Jun 17, 2026

Body Composition Outcomes in MS Patients

An observational study in Obesity, sponsored by Pennington Biomedical Research Center. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Pennington Biomedical Research Center · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 67 studies in Obesity by Pennington Biomedical Research Center — 9 open to participants now, 13 under way, none of them phase 3. Obesity · Pennington Biomedical Research Center.

Planned enrollment
16th of 22
20 · median 47
Started
2026
with 4 others
Observational
22 of 67
3 open now
Primary completion
2027-02
later than 7 of 12 live
Registered
62nd of 67
by date

Among the 67 studies in Obesity by Pennington Biomedical Research Center, this one is the 16th largest by planned enrollment of the 22 observational ones that give a count, is one of 5 that started in 2026, is one of 22 observational ones, reaches primary completion later than 7 of the 12 other live ones, and was the 62nd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 67 studies in Obesity by Pennington Biomedical Research Center are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Obesity by Pennington Biomedical Research Center, or all of them as a file.
02

Study summary

Objectives The objective of this project is to generate pilot data substantiating our hypothesis that advanced body composition measurement tools will provide more accurate and clinically relevant data on the outcomes of metabolic surgery (MS) in patients with severe obesity compared to traditional methods.

To achieve this objective, the investigators propose the following aims:

Aim 1: Evaluate the effectiveness of different body composition measurement tools in assessing outcomes in patients with severe obesity undergoing MS.

Aim 2: Assess the changes in body composition and muscle strength following MS.

Aim 3: Compare body compositions changes between SG and RYGB patients.

Read the detailed description

Background Metabolic surgery (MS) is the most effective long term obesity treatment in patients with severe obesity. The prevalence of obesity among US adults is 40.3% and the prevalence of severe obesity is 9.4% (2021-2023). Despite the prevalence and severity of obesity, there is a significant knowledge gap regarding the most effective tools for assessing body composition in this population. Traditional methods such as BMI and waist circumference may not accurately reflect changes in body composition, particularly in patients with higher BMI. Current literature on body composition measurements in patients with severe obesity undergoing bariatric surgery is limited.

Our study design and rationale are inspired by a 2003 study by Das et al., which assessed body composition using four measurement tools: the 3-compartment (3C) model, isotope dilution, densitometry, and BIA. This study involved 20 women with BMIs ranging from 37 to 76 who underwent RYGB. The findings indicated that a simple 3-compartment model using air displacement plethysmography and BIA is effective for clinical evaluation in this population. To date, this remains the only study focusing on higher BMI patients undergoing MS. However, its limitations include being conducted solely on a female population and using these four measurement tools exclusively in RYGB patients with severe obesity.

As mentioned earlier, the goal of this project is to generate pilot data substantiating our hypothesis that advanced body composition measurement tools will provide more accurate and clinically relevant data on the outcomes of MS in patients with severe obesity compared to traditional methods.

Objectives The objective of this project is to generate pilot data substantiating our hypothesis that advanced body composition measurement tools will provide more accurate and clinically relevant data on the outcomes of metabolic surgery (MS) in patients with severe obesity compared to traditional methods.

To achieve this objective, the investigators propose the following aims:

Aim 1: Evaluate the effectiveness of different body composition measurement tools in assessing outcomes in patients with severe obesity undergoing MS. The investigators hypothesize that advanced body composition measurement tools will provide more accurate and clinically relevant data on the outcomes of MS in patients with severe obesity compared to traditional methods.

Aim 2: Assess the changes in body composition and muscle strength following MS. The investigators hypothesize that 6 months post MS, patients will experience a change in muscle strength, along with a more significant decrease in fat mass compared to muscle mass.

Aim 3: Compare body compositions changes between SG and RYGB patients. The investigators hypothesize that RYGB patients will experience greater changes in subcutaneous, visceral, and total fat compared to SG patients after 6 months.

03

Conditions studied

  • Obesity

Keywords

  • Obesity
  • Bariatric surgery
  • skeletal muscle
  • adipose tissue
  • weight loss
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Bariatric surgery patients with BMI 40 or more

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being either male or female
  • Being an adult greater or equal to 18 years of age
  • ≥40 kg/m2
  • Weigh less than 440 pounds
  • Being willing to comply with the study procedures
  • Being scheduled for primary metabolic surgery (either Sleeve Gastrectomy or Roux-en-Y Gastric bypass)

Exclusion criteria

Exclusion Criteria:

  • Previous bariatric surgery or other complex abdominal surgery
  • Poorly controlled medical or psychiatric disorders
  • For women in child-bearing ages, being pregnant or attempting to become pregnant or currently breastfeeding
  • Having metal-containing objects in their body that may cause artifact on MRI
  • Having medical implants such as a pacemaker or metal joint replacements
  • Having a body weight greater than 440 pounds
  • Comorbid conditions that may affect body composition measurements, such as advanced liver disease or severe cardiovascular disease.
  • Cannot understand risks, benefits, and compliance required to participate.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Roux-en-Y gastric bypass surgery

  • Cohort 2

    Sleeve Gastrectomy

06

What researchers measure

Primary outcomes

  1. Evaluate the effectiveness of Bioimpedance Analysis (BIA) in assessing outcomes in patients with severe obesity undergoing metabolic surgery (MS).

    Measurement of weight in kilograms

    Time frame: Baseline and 6 months

  2. Evaluate the effectiveness of Leg Strength and Endurance Testing in assessing outcomes in patients with severe obesity undergoing MS.

    Leg muscle strength measured in in Newton-meters (Nm)

    Time frame: Baseline and 6 months

  3. Evaluate the effectiveness of BIA in assessing outcomes in patients with severe obesity undergoing MS

    height in meters

    Time frame: Baseline and 6 months

  4. Evaluate the effectiveness of BIA in assessing outcomes in patients with severe obesity undergoing MS

    weight and height will be combined to report BMI in kg/m\^2

    Time frame: Baseline and 6 months

  5. Evaluate the effectiveness Body MRI in assessing outcomes of body composition in assessing outcomes in patients with severe obesity undergoing MS

    Measure skeletal muscle mass volume in cm\^3

    Time frame: Baseline and 6 months

  6. Evaluate the effectiveness of BIA in assessing outcomes in patients with severe obesity undergoing MS

    body fat percentage in %

    Time frame: Baseline and 6 months

  7. Evaluate the effectiveness of anthropometric measurement tool in assessing outcomes in patients with severe obesity undergoing MS

    Measure waist circumference in cm

    Time frame: Baseline and 6 months

  8. Evaluate the effectiveness of anthropometric measurement tool in assessing outcomes in patients with severe obesity undergoing MS

    Mid-thigh circumference in cm

    Time frame: Baseline and 6 months

  9. Evaluate the effectiveness of BIA measurement tool in assessing outcomes in patients with severe obesity undergoing MS

    weight and height will be combined to report BMI in kg/m\^2

    Time frame: Baseline and 6 months

  10. Evaluate the effectiveness of anthropometric measurement tools in assessing outcomes in patients with severe obesity undergoing MS

    Hip circumference in cm

    Time frame: Baseline and 6 months

  11. Evaluate the effectiveness Body MRI in assessing outcomes of body composition in assessing outcomes in patients with severe obesity undergoing MS

    Measure visceral adipose tissue volume in cm\^3

    Time frame: Baseline and 6 months

  12. Evaluate the effectiveness Body MRI in assessing outcomes of body composition in assessing outcomes in patients with severe obesity undergoing MS

    Measure subcutaneous adipose tissue volume in cm\^3

    Time frame: Baseline and 6 months

  13. Evaluate the effectiveness of Six-Minute Walk testing in assessing outcomes in patients with severe obesity undergoing MS.

    Physical endurance will be measured by the distance walked during a 6-minute walk test in meter

    Time frame: Baseline and 6 months

  14. Evaluate the effectiveness of 3D Optical Imaging in assessing outcomes in patients with severe obesity undergoing MS.

    Measure body volume in cm\^3

    Time frame: Baseline and 6 months

  15. Evaluate the effectiveness of BodPod (Air Displacement Plethysmography) in assessing outcomes in patients with severe obesity undergoing MS

    Measure body volume in liters

    Time frame: Baseline and 6 months

  16. Evaluate the effectiveness of BodPod in assessing outcomes in patients with severe obesity undergoing MS.

    Measure body density in kilograms per cubic meter (kg/m\^3)

    Time frame: Baseline and 6 months

  17. Evaluate the effectiveness of Dual Energy X ray Absorptiometry (DXA) in assessing outcomes in patients with severe obesity undergoing MS

    Measure total fat mass in kg

    Time frame: Baseline and 6 months

  18. Evaluate the effectiveness of DXA in assessing outcomes in patients with severe obesity undergoing MS

    Measure lean mass /fat free mass in kg

    Time frame: Baseline and 6 months

  19. Evaluate the effectiveness of Deuterium & Bromide Dilution in assessing outcomes in patients with severe obesity undergoing metabolic surgery (MS).

    Measure total body water in liter

    Time frame: Baseline and 6 months

  20. Evaluate the effectiveness of Deuterium & Bromide Dilution in assessing outcomes in patients with severe obesity undergoing MS.

    Measure extracellular water in liters

    Time frame: Baseline and 6 months

07

Study locations

1 of 2 sites recruiting
  • Pennington Biomedical Resarch Center
    Baton Rouge, Louisiana 70808, United States
    Not yet recruiting
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
    Recruiting
08

References and documents

Publications

  • 1. Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, De Luca M, Faria SL, Goodpaster KP, Haddad A, Himpens JM. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery. 2. Courcoulas AP, Daigle CR, Arterburn DE. Long term outcomes of metabolic/bariatric surgery in adults. BMJ. 2023 Dec 18;383. 3. Pareek M, Schauer PR, Kaplan LM, Leiter LA, Rubino F, Bhatt DL. Metabolic surgery: weight loss, diabetes, and beyond. Journal of the American College of Cardiology. 2018 Feb 13;71(6):670-87. 4. Hanipah ZN, Schauer PR. Bariatric surgery as a long-term treatment for type 2 diabetes/metabolic syndrome. Annual review of medicine. 2020 Jan 27;71(1):1-5. 5. Emmerich SD, Fryar CD, Stierman B, Ogden CL. Obesity and Severe Obesity Prevalence in Adults: United States, August 2021-August 2023. 6. Zhao L, Park S, Ward ZJ, Cradock AL, Gortmaker SL, Blanck HM. Peer Reviewed: State-Specific Prevalence of Severe Obesity Among Adults in the US Using Bias Correction of Self-Reported Body Mass Index. Preventing Chronic Disease. 2023;20. 7. Das SK, Roberts SB, Kehayias JJ, Wang J, Hsu LG, Shikora SA, Saltzman E, McCrory MA. Body composition assessment in extreme obesity and after massive weight loss induced by gastric bypass surgery. American Journal of Physiology-Endocrinology and Metabolism. 2003 Jun 1;284(6):E1080-8. 8. Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. International Journal of Obesity. 2000;24(1):38-48. 9. Meule A, Hermann T, Kübler A. A short version of the Food Cravings Questionnaire-Trait: the FCQ-T-reduced. Frontiers in Psychology. 2014;5:190. 10. Diktas HE, Cardel MI, Foster GD, LeBlanc MM, Dickinson SL, Ables EM, Martin CK. Development and validation of the Food Noise Questionnaire. Obesity. 2

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Feb 2027, 9 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 9 months is below that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Apr 15, 2026
StartActual
Apr 14, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Mar 31, 2027
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07530718
Collaborators
Our Lady of the Lake Hospital
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
Apr 14, 2026
Primary completion
Feb 1, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jun 17, 2026

Study contacts

Zubaidah Nor Hanipah, MD
Contact
zubaidah.norhanipah@pbrc.edu
225-763-2831

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion